Myasthenia gravis (gMB) is a rare chronic condition that causes weakness if voluntary muscles including muscles in the face, throat and muscles connecting to a person’s bones. It is an autoimmune disease meaning the body’s defence system attacks healthy cells or proteins mistakenly.

4MCS are running a clinical trial to test a new medication versus a non-active substance (placebo) to see if it can improve symptoms of myasthenia gravis.

Eligibility Criteria

• Male or female between ages 18-75 years old
• Diagnosis of Myasthenia gravis
• On a stable standard of care gMB treatment
• Other criteria with apply based on medical history